ANTI-TUMOR ACTIVITY OF CLOMIPHENE ANALOGS INVITRO - RELATIONSHIP TO AFFINITY FOR THE ESTROGEN-RECEPTOR AND ANOTHER HIGH-AFFINITY ANTIESTROGEN-BINDING SITE

被引：49

作者：

MURPHY, LC ^{[1
]}

SUTHERLAND, RL ^{[1
]}

机构：

[1] UNIV SYDNEY, LUDWIG INST CANC RES, SYDNEY, NSW 2006, AUSTRALIA

来源：

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM | 1983年 / 57卷 / 02期

关键词：

D O I：

10.1210/jcem-57-2-373

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：373 / 379

页数：7

共 42 条

[31] 2-PHENYLBENZO[B]FURANS - RELATIONSHIP BETWEEN STRUCTURE, ESTROGEN-RECEPTOR AFFINITY AND CYTOSTATIC ACTIVITY AGAINST MAMMARY-TUMOR CELLS [J].

ERBER, S ;

RINGSHANDL, R ;

VONANGERER, E .

ANTI-CANCER DRUG DESIGN, 1991, 6 (05) :417-426

[32] Structural similitudes between cytotoxic antiestrogen-binding site (AEBS) ligands and cytotoxic sigma receptor ligands. Evidence for a relationship between cytotoxicity and affinity for AEBS or sigma-2 receptor but not for sigma-1 receptor [J].

Kedjouar, B ;

Daunes, S ;

Vilner, BJ ;

Bowen, WD ;

Klaebe, A ;

Faye, JC ;

Poirot, M .

BIOCHEMICAL PHARMACOLOGY, 1999, 58 (12) :1927-1939

[33] DOWN-MODULATION OF INTERLEUKIN-6 GENE-EXPRESSION BY 17-BETA-ESTRADIOL IN THE ABSENCE OF HIGH-AFFINITY DNA-BINDING BY THE ESTROGEN-RECEPTOR [J].

RAY, A ;

PREFONTAINE, KE ;

RAY, P .

JOURNAL OF BIOLOGICAL CHEMISTRY, 1994, 269 (17) :12940-12946

[34] The ryanodine receptor pore blocker neomycin also inhibits channel activity via a previously undescribed high-affinity Ca2+ binding site [J].

Laver, Derek R. ;

Hamada, Tomoyo ;

Fessenden, James D. ;

Ikemoto, Noriaki .

JOURNAL OF MEMBRANE BIOLOGY, 2007, 220 (1-3) :11-20

[35] The Ryanodine Receptor Pore Blocker Neomycin also Inhibits Channel Activity via a Previously Undescribed High-Affinity Ca2+ Binding Site [J].

Derek R. Laver ;

Tomoyo Hamada ;

James D. Fessenden ;

Noriaki Ikemoto .

Journal of Membrane Biology, 2007, 220 :11-20

[36] MAMMARY-TUMOR INHIBITING ACETOXY SUBSTITUTED 1,1,2-TRIPHENYLBUTENES - RELATIONSHIP BETWEEN STRUCTURE, ESTRADIOL-RECEPTOR AFFINITY AND ANTI-TUMOR ACTIVITY [J].

SCHNEIDER, MR ;

MICHEL, RT .

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 1981, 99 (03) :A55-A56

[37] In vivo and In vitro Screening of high affinity Vasoactive Intestinal Peptide receptor antagonists with potent anti-tumor activity in murine models of Acute Myeloid Leukemia [J].

Wang, Yuou ;

Li, Jian-Ming ;

Passang, Tenzin ;

Li, Yiwen ;

Giver, Cynthia ;

Waller, Edmund .

JOURNAL OF IMMUNOLOGY, 2024, 212 (01)

[38] Isolation of a high-affinity stable single-chain Fv specific for mesothelin from DNA-immunized mice by phage display and construction of a recombinant immunotoxin with anti-tumor activity [J].

Chowdhury, PS ;

Viner, JL ;

Beers, R ;

Pastan, I .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (02) :669-674

[39] High affinity NK cells expressing a PD-L1 chimeric antigen receptor demonstrate anti-tumor activity in head and neck cancer through multiple distinct mechanisms [J].

Robbins, Yevtte ;

Friedman, Jay ;

Greene, Sarah ;

Fabian, Kellsye ;

Padget, Michelle ;

Lee, John ;

Soon-Shiong, Patrick ;

Niazi, Kayvan ;

Sender, Lennie ;

Boissel, Laurent ;

Schlom, Jeffrey ;

Hodge, James ;

Allen, Clint .

JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7

[40] High target binding affinity with long lasting cellular target engagement and high dose intermittent schedule of PI3K inhibitor copanlisib contribute to the potent anti-tumor activity and good safety profile [J].

Fernandez-Montalvan, Amaury E. ;

Georgi, Victoria ;

Vasta, James ;

Glaeske, Sarah ;

Puetter, Vera ;

Robers, Matthew B. ;

Moenning, Ursula ;

Sturz, Andrea ;

Lefranc, Julien ;

Ziegelbauer, Karl ;

Brands, Michael ;

Stegmann, Christian ;

Scott, William J. ;

Liu, Ningshu .

CANCER RESEARCH, 2017, 77

← 1 2 3 4 5 →